Mode
Text Size
Log in / Sign up
N/A N=29,453 Randomized Diagnostic

The Digital Breast Tomosynthesis Trial in Bergen

Breast Neoplasms

Enrolled (actual)
29,453
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcome: Primary: Number of Participants With Screen-Detected Breast Cancer — 95; 87 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Synthetic Mammography + Digital Breast Tomosynthesis (Radiation); Digital mammography (Radiation)
Age
Adult, Older Adult · 48+ yrs
Sex
Female
Sponsor
Norwegian Institute of Public Health
Primary completion
Jun 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Screen-Detected Breast Cancer
95; 87
SECONDARY
Number and Percentage of Participants Screen-Detected Breast Cancer Among Participants Recalled for Further Assesment
95; 87
SECONDARY
Number of Participants Recalled for Further Assesment Due to Mammographic Findings
444; 571
SECONDARY
Incremental Costs of Screening With Tomosynthesis Versus Digital Mammography
8.5; 6.2
SECONDARY
Prognostic and Predictive Tumor Characteristics for Screen-Detected Breast Cancer
62; 51; 6; 13; 2; 4
SECONDARY
Number of Participants With Interval Breast Cancer
20; 29

Summary

Compare synthetic mammography+digital breast tomosynthesis (SM+DBT) with digital mammography (DM) as a screening tool for women aged 50-69 years, invited to participate in the Norwegian Breast Cancer Screening Program at the screening unit in Bergen, Norway, with regard to early performance measures, including prognostic and predictive tumor characteristics, radiation doses and cost-effectiveness.

Eligibility Criteria

Inclusion Criteria

  • Informed consent

Exclusion Criteria

  • Breast implants
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02835625). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search